Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-PanTumor02 of ifinatamab deruxtecan in recurrent or metastatic solid tumors
jRCT2031240016Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ifinatamab deruxtecan in Nonhematologic neoplasms, endometrial cancer (EC), endometrial carcinosarcoma and 16 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate, Dose-limiting toxicities in the hepatocellular carcinoma cohort and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)endometrial carcinosarcomahead and neck squamous cell carcinoma (HNSCC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031240016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240016.